184 related articles for article (PubMed ID: 23152373)
21. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study.
Knopp RH; Tsunehara C; Retzlaff BM; Fish B; Nguyen H; Anderson S; Nguyen T
Metabolism; 2006 Dec; 55(12):1697-703. PubMed ID: 17142146
[TBL] [Abstract][Full Text] [Related]
22. Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence.
Aday AW; Lawler PR; Cook NR; Ridker PM; Mora S; Pradhan AD
Circulation; 2018 Nov; 138(21):2330-2341. PubMed ID: 30021845
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial.
Insull W; Toth P; Mullican W; Hunninghake D; Burke S; Donovan JM; Davidson MH
Mayo Clin Proc; 2001 Oct; 76(10):971-82. PubMed ID: 11605698
[TBL] [Abstract][Full Text] [Related]
24. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
[TBL] [Abstract][Full Text] [Related]
25. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
[TBL] [Abstract][Full Text] [Related]
26. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.
Davidson MH; Dillon MA; Gordon B; Jones P; Samuels J; Weiss S; Isaacsohn J; Toth P; Burke SK
Arch Intern Med; 1999 Sep; 159(16):1893-900. PubMed ID: 10493319
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
Davidson M
Clin Ther; 2013 Aug; 35(8):1247-52. PubMed ID: 23916045
[TBL] [Abstract][Full Text] [Related]
28. Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size.
Suter PM; Marmier G; Veya-Linder C; Hänseler E; Lentz J; Vetter W; Otvos J
Atherosclerosis; 2005 May; 180(1):127-35. PubMed ID: 15823285
[TBL] [Abstract][Full Text] [Related]
29. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
[TBL] [Abstract][Full Text] [Related]
30. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.
Garvey WT; Kwon S; Zheng D; Shaughnessy S; Wallace P; Hutto A; Pugh K; Jenkins AJ; Klein RL; Liao Y
Diabetes; 2003 Feb; 52(2):453-62. PubMed ID: 12540621
[TBL] [Abstract][Full Text] [Related]
31. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.
Festa A; Williams K; Hanley AJ; Otvos JD; Goff DC; Wagenknecht LE; Haffner SM
Circulation; 2005 Jun; 111(25):3465-72. PubMed ID: 15983261
[TBL] [Abstract][Full Text] [Related]
32. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia.
Mackness MI; Bhatnagar D; Durrington PN; Prais H; Haynes B; Morgan J; Borthwick L
Eur J Clin Nutr; 1994 Dec; 48(12):859-65. PubMed ID: 7889894
[TBL] [Abstract][Full Text] [Related]
33. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy.
Jenkins AJ; Lyons TJ; Zheng D; Otvos JD; Lackland DT; McGee D; Garvey WT; Klein RL;
Kidney Int; 2003 Sep; 64(3):817-28. PubMed ID: 12911531
[TBL] [Abstract][Full Text] [Related]
34. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.
Soedamah-Muthu SS; Chang YF; Otvos J; Evans RW; Orchard TJ;
Diabetologia; 2003 May; 46(5):674-82. PubMed ID: 12743701
[TBL] [Abstract][Full Text] [Related]
35. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia.
Perry CM
Paediatr Drugs; 2010 Apr; 12(2):133-40. PubMed ID: 20218749
[TBL] [Abstract][Full Text] [Related]
36. High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study.
Wojczynski MK; Glasser SP; Oberman A; Kabagambe EK; Hopkins PN; Tsai MY; Straka RJ; Ordovas JM; Arnett DK
Lipids Health Dis; 2011 Oct; 10():181. PubMed ID: 22008512
[TBL] [Abstract][Full Text] [Related]
37. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
39. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.
Chan SY; Mancini GB; Ignaszewski A; Frohlich J
BMC Clin Pharmacol; 2008 Oct; 8():10. PubMed ID: 18957124
[TBL] [Abstract][Full Text] [Related]
40. Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes.
Mostad IL; Bjerve KS; Lydersen S; Grill V
Eur J Clin Nutr; 2008 Mar; 62(3):419-29. PubMed ID: 17327864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
